[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-fibrosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-fibrosis":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,32,0,25,[9,50,81,115,152,179,206,237,259,281,299,325,346,371,393,420,443,469,495,516,540,567,604,625,644],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100626882","phase-3-long-term-extension-study-to-evaluate-safety-and-tolerability-of-admilparant-in-participants-with-pulmonary-fibrosis-100626882",false,"NCT07441408","Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis","An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis","Inclusion Criteria:\n\n\\- Participants must have completed participation in either IM027068 or IM0271015 (defined as receiving study intervention (IMP) until completion of EOT visit).\n\nExclusion Criteria:\n\n* Clinically significant AE that resulted in discontinuation or interruption of IMP (Investigational Medicinal Product) in IM027068 or IM0271015 without reinitiation of IMP.\n* Exhibit symptoms of heart failure at rest.\n* History of lung reduction surgery or lung transplant. Note: Being on the transplantation list is allowed.\n* Participants with known PAH (Pulmonary Arterial Hypertension) who has been on single drug therapy that now requires multi-drug therapy.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL",{"count":19,"type":20},2277,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).",[26],"Pulmonary Fibrosis",[28,29,30,31,32,33,34,35,36],"LPA1 receptor antagonist","Idiopathic pulmonary fibrosis","Progressive pulmonary fibrosis","Long-term extension","IPF","PPF","IM027068","IM0271015","Follow up","NOT_YET_RECRUITING","2026-07-01",{"date":40,"type":41},"2026-07-02","ACTUAL",{"date":43,"type":20},"2026-12-16",{"date":45,"type":20},"2030-03-30",{"name":47,"class":48},"Bristol-Myers Squibb","INDUSTRY",275,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100528600","single-time-point-prediction-as-earlier-diagnosis-of-progressive-pulmonary-fibrosis-100528600","NCT06162884","Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis","Imaging Signature of Progressive Pulmonary Fibrosis in Idiopathic Pulmonary Fibrosis and Non-IPF Interstitial Lung Diseases","IS-PPF","IPF Inclusion Criteria:\n\n* Established a diagnosis (within 5 years) of IPF by enrolling center as defined by ATS\u002FERS\u002FJRS\u002FALAT criteria\n* Age over or equal to 40 years old\n* No history of lung transplant\n* FVC % predicted \\>= 45%\n* DLCO % predicted \\>=25%\n* Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control. WOCBP taking oral contraceptives (OCs) also have to use one barrier method.\n\nNon-IPF ILD Inclusion Criteria:\n\n* Established a diagnosis (within 5 years) of non-IPF ILD by enrolling center.\n* Age over or equal to 18 years old\n* Presence of chronic fibrosis ILD defined as architectural distortions with reticulation and the presence of traction bronchiectasis by visual assessment: (1) estimating visually \\>5% in whole lung, or (2) mild pulmonary fibrosis and \\\u003C5% in whole lung (i.e., early non-IPF-ILD identified by a pulmonologist).\n* Patients treated with immunosuppressive agents (other than corticosteroids) for an underlying systemic disease need to be on a stable treatment for at least 12 weeks prior to screening\n* FVC % predicted \\>= 45%\n* DLCO % predicted \\>=25%\n* Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control. WOCBP taking oral contraceptives (OCs) also have to use one barrier method\n\nExclusion Criteria:\n\n* Planned to participate in an intervention trial within the next 6 months\n* Currently listed for lung transplantation at the time of enrollment\n* Malignancy, treated or untreated, other than malignancy unlikely to affect prognosis in the next 3 years such as skin cancer or non-metastatic prostate cancer within the past 5 years\n* Any clinically significant co-morbidity, which in the view of investigator, is likely to contribute to mortality or ability to perform PFT's in the next 2 years\n* Prebronchodilator Forced Expiratory Volume in 1 second (FEV1)\u002FForced vital capacity (FVC) \\\u003C0.7 at as screening\n* Exclusion of co-morbidities: congestive heart failure (stroke, deep vein thrombosis, pulmonary embolism, myocardial infarction), current virus-associated community acquired pneumonia, smoking-related chronic obstructive lung disease with FEV1 \\\u003C70%, history of lung cancer, history of other cancer treated within the past 4 years for IPF and 5 years for non-IPF ILD (excluding basal cell carcinoma of skin).\n\nHRCT data from subjects with combined pulmonary fibrosis and emphysema (CPFE) can be collected.\n\nMajor Discontinuing Criteria in this study\n\n* lung transplant after baseline or death\n* withdraw of consent or transition to another care center","18 Years",{"count":60,"type":20},200,"OBSERVATIONAL","This study is a prospective observational study for subjects with idiopathic pulmonary fibrosis (IPF) or non-IPF interstitial lung diseases (ILD).\n\nThe purpose of this study is to compare whether imaging patterns from high-resolution computed tomography (HRCT) at baseline can predict worsening. Single Time point Prediction (STP) is a score derived from an artificial intelligenc\u002F machine learning (AI\u002FML) using the radiomic features from a HRCT scan that quantifies the imaging patterns of short-term predictive worsening.",[26],[65,66,67,68],"imaging outcome","Single Timepoint Prediction","AI\u002Fmachine learning","progressive ILD","RECRUITING","2026-06-16",{"date":72,"type":41},"2026-06-18",{"date":74,"type":41},"2024-11-06",{"date":76,"type":20},"2029-08-19",{"name":78,"class":79},"University of California, Los Angeles","OTHER",1,{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":17,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":93,"conditions":94,"keywords":99,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":4,"leadSponsor":111,"locationsCount":114},"100054548","role-of-genetic-factors-in-the-development-of-lung-disease-100054548","NCT00001532","Role of Genetic Factors in the Development of Lung Disease","Role of Genetic Factors in the Pathogenesis of Lung Disease","* INCLUSION CRITERIA:\n\nInclusion criteria for patients with AAT deficiency include: (1) Diagnosis of AAT with a confirmed phenotype considered in the high risk category; (2) Clinical phenotype consistent with potential genetic diseases and other genetic causes of lung diseases (3) symptoms consistent with pulmonary disease; (4) chest x-ray consistent with pulmonary disease; (5) pulmonary function tests consistent with pulmonary disease; (6) smokers, defined as individuals who are current smokers (1 pack per day for at least 2 years) and nonsmokers, defined as never-smokers or ex-smokers who have quit smoking three or more years ago;\n\nInclusion criteria for individuals with chronic obstructive pulmonary diseases include:\n\n1. symptoms consistent with pulmonary disease\n2. chest x-ray consistent with pulmonary disease\n3. pulmonary function tests consistent with pulmonary disease;\n4. smokers, defined as individuals who are current smokers (1 pack per day for at least 2 years) and nonsmokers, defined as never-smokers or ex-smokers who have not smoked for three or more years.\n\nInclusion criteria for patients with cystic fibrosis include a defined genetic mutation (i.e., any of the known variants of the CFTR gene, such as delta F508 allele) or a cystic fibrosis phenotype and clinical features consistent with this disease. Children with cystic fibrosis over eight years of age may be included.\n\nPatients with established diagnoses of sarcoidosis; mycobacterial infections; TSC (definite or possible); cystic lung diseases including genetic diseases; lymphangioleiomyomatosis or diseases associated with lymphatic disorders; history of pneumothorax; pulmonary fibrosis; asthma; histiocytosis X and diabetes mellitus will be included in this protocol. Relatives of patients may also be seen under this protocol. Children with lymphangiomatosis who are two years of age or older may be included. Participants with asthma may be enrolled at Suburban Hospital.\n\nResearch volunteers in the pulmonary control group are defined as individuals with no pulmonary disease (e.g. rheumatoid arthritis without evidence of pulmonary disease). Research volunteers in the diabetes control group are defined as individuals with no history of diabetes, coronary artery disease, or pulmonary disease.\n\nPregnant and or nursing women can be included in accordance with Federal Regulations at Subpart B of 45 CFR 46. Subjects who are pregnant and or nursing will be excluded from procedures during their pregnancy that are greater than minimal risk, until they are no longer pregnant and\u002For nursing. Procedures that will not be completed while the subject is pregnant and\u002For nursing including: PFTs, Six Minute Walk Test, thoracentesis, bronchoscopy, and measurements with imaging modalities requiring contrast or with radiation exposure such as Chest x-ray, CT scan, MRI. Allowing subjects to be included in the study may glean important information about individuals with uncommon pulmonary disease during and post pregnancy.\n\nPatients with abnormalities in ADP-ribosyltransferases, ADP-ribosyl-acceptor hydrolases, and their substrates. Children who are two years of age or older may be studied if they have a known defect in ADP-ribosylation, or if they have a family member with a defect in ADP-ribosylation and may be affected.\n\nEXCLUSION CRITERIA:\n\nExclusion criteria for all participants include:\n\n1. age less than 18 or greater than 90 except for NIH patients with diseases \u002Fdisorders as described in this protocol (except cystic fibrosis, lymphangiomatosis or defects in ADP-ribosylation) who are 16 years of age or older, patients with cystic fibrosis who are over eight years of age, patients who are two years of age or older with lymphangiomatosis or a known defect in ADP-ribosylation, or who have a family member with a defect in ADP-ribosylation, or unless patient-specific IRB approval is obtained and;\n2. inability to obtain reliable pulmonary function testing. As clarification, healthy volunteers, relatives of patients (except as noted for an ADP-ribosylation defect), and asthmatic patients from Suburban Hospital will be excluded if less than 18 or greater than 90 years of age.\n\nExclusion criteria for participating in the bronchoscopy portion of the study are:\n\n1. presence of any contraindication for fiberoptic bronchoscopy, with lavage and\u002For bronchial brushing;\n2. advanced stage of a pulmonary or a systemic illness such that the risk is judged to be significant even in the absence of a specific contraindication to the procedure\n3. allergy to topical anesthetic (e.g., lidocaine)\n4. current or recent respiratory infection (within the last 4 weeks)\n5. pregnancy or lactation\n6. age less than 18 or greater than 65.",true,"2 Years","90 Years",{"count":92,"type":20},3500,"This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease.\n\nThe study will focus on defining the distribution of abnormal genes responsible for processes directly involved in different diseases affecting the lungs of patients and healthy volunteers.\n\nOptional CT Sub-study\n\nThe standard CT scan will be compared to the low dose radiation CT scan for the 150 subjects enrolled in the sub-study to assess the variation between the two techniques. Specifically, the quantitative computer aided detection of lung CT abnormalities from LAM can be compared to assess whether low radiation dose CT exams is an alternative to conventional CT to monitor disease\n\nstatus.\n\nThis optional sub-study will be offered to up to 100 adult subjects with lung disease and up to 50 children age 9 and older with CF. Children will not be enrolled in the optional CT sub-study unless they have had a standard CT scan for medical purposes to use in comparison. One additional low dose radiation CT scan of the chest may be done as part of this sub-study when these subjects have their next annual CT scan.",[95,26,96,97,98],"Cystic Fibrosis","Tuberous Sclerosis","Asthma","Pulmonary Sarcoidosis",[100,101,102,103,104,105,106,95,97],"Genetic Polymorphism","Nitric Oxide Synthesis","Alpha 1-Antitrypsin","Candidate Genes","Lung Pathology","Natural History","Lung Disease","2026-06-13",{"date":70,"type":41},{"date":110,"type":41},"1996-09-13",{"name":112,"class":113},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",2,{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":125,"conditions":126,"keywords":134,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":151},"100640851","safety-of-bronchoscopy-in-patients-with-interstitial-lung-disease-100640851","NCT07627594","Safety of Bronchoscopy in Patients With Interstitial Lung Disease","Safety of Bronchoscopy in Patients With Interstitial Lung Disease: A Prospective, Observational, Multicentre, International Study","SaBrILD","Inclusion Criteria:\n\n* Consecutive adult (≥18 years old) patients with suspected or confirmed ILD who need to undergo bronchoscopy as part of their routine clinical practice,\n* Patients able to understand and sign an informed consent\n\nExclusion Criteria:\n\n* Patients who refused the study partecipation;\n* Patients with contraindications to bronchoscopy",{"count":124,"type":20},427,"Bronchoscopy is an essential technique, routinely used in the differential diagnosis workup of many Interstitial Lung Diseases (ILDs) and in referral centres is a common procedure. Bronchoalveolar lavage (BAL), bronchial and transbronchial biopsies with forceps and cryoprobes, and lymph node sampling with endosonography represent the most used sampling techniques in these patients. However, patients with ILDs refer to medical attention in a wide range of clinical conditions from mild functional impairment, with absent or few respiratory symptoms, to severe lung involvement with low exercise tolerance and\u002For chronic respiratory failure. In these patients, a balance between benefits and risk, i.e. to the safety and diagnostic utility of bronchoscopy should be always carefully evaluated. Moreover, there is a wide variability in adverse events entity and frequency depending by procedures performed during bronchoscopy.\n\nDespite its crucial utility, only few data are available in the literature on the safety of bronchoscopy in patients with ILDs and limited data on the utility and safety of this sampling technique are present in patients with AE-ILDs.\n\nThe primary aim of this study is to assess the overall rate of complications occurring within 24 hours after bronchoscopy. Study rate and type of complications occurring during the endoscopic procedure, within 30 days after bronchoscopy, in patients with AE-ILDs, among fibrotic Vs non-fibrotic ILD, and according to each employed sampling technique will be also recorded.",[127,128,129,130,131,132,133,26],"Interstitial Lung Disease (ILD)","Bronchoscopy","Bronchoalveolar Lavage (BAL)","Acute Exacerbation","Cryobiopsy","Transbronchial Biopsy","Endosonography",[135,136,137,138,139,140,141],"ILD","BAL","acute exacerbation","cryobiopsy","transbronchial biopsy","interstitial lung disease","pulmonary fibrosis","2026-05-29",{"date":144,"type":41},"2026-06-04",{"date":146,"type":20},"2026-06-01",{"date":148,"type":20},"2028-05-30",{"name":150,"class":79},"University of Milan",11,{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":21,"phases":162,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":151},"100583985","implementation-of-home-monitoring-in-patients-with-pulmonary-fibrosis-100583985","NCT06883448","Implementation of Home Monitoring in Patients With Pulmonary Fibrosis","The SUITS Study: Implementation of Home Monitoring in Patients With Pulmonary Fibrosis","SUITS","Inclusion Criteria:\n\n* A multidisciplinary ILD team diagnosis of pulmonary fibrosis according to ATS\u002FERS\u002FJRS\u002FALAT guidelines;\n* Adults (=\u002F\\>18 years).\n\nExclusion Criteria:\n\n* Patients who are not able to speak, read and\u002For write in Dutch;\n* Patients with no access to the internet;\n* Patients with a life expectancy of less than 1 year as determined by the treating healthcare provider;\n* Patients who are or have been using a home monitoring program for PF.",{"count":161,"type":20},220,[163],"NA","The objective of this study is to evaluate the impact of structurally replacing half of the outpatient clinic visits for patients with pulmonary fibrosis by home monitoring and video consultations on patient self-management and health(care) outcomes.",[26,127],[167,168,169],"eHealth","Hybrid care","Self-management","2026-05-22",{"date":172,"type":41},"2026-05-27",{"date":174,"type":41},"2024-10-02",{"date":176,"type":20},"2027-09-01",{"name":178,"class":79},"Erasmus Medical Center",{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":21,"phases":189,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":4},"100636838","phase-4-this-is-a-trial-designed-to-evaluate-the-combination-of-nerandomilast-with-mycophenolate-across-a-wide-variety-of-pulmonary-fibrosis-subtypes-with-the-aim-of-providing-clinicians-with-assurance-that-this-is-an-appropriate-therapeutic-combination-100636838","NCT07570888","This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination.","Nerandomilast Added to Mycophenolate for Treatment of Pulmonary Fibrosis (NERAM-PF).","NERAM-PF","Inclusion Criteria:\n\n* Any underlying pulmonary fibrosis diagnosis (excluding IPF) with ≥ 10% fibrosis on chest HRCT (performed within 1 year of screening) by volume assessment as determined by the treating physician\n* Anticipated benefit from nerandomilast therapy as determined by the treating physician (note that previous observed progression as defined in previous PPF clinical trials is not required prior to enrolment)\n* Stable dose of mycophenolate for the preceding 3 months, with a minimum total daily dose of 1,500mg for mycophenolate mofetil or 1080mg for mycophenolate sodium\n* Clinically stable for the preceding 6 weeks (did not require addition of corticosteroids for AE-ILD, or any other reason for urgent hospitalization).\n\nExclusion Criteria:\n\n* Diagnosis of IPF\n* Contraindication to treatment with nerandomilast as determined by the treating physician\n* FVC \\\u003C 45% or DLCO \\\u003C 25% based on last PFT (must be performed within 3 months of screening)\n* Use of systemic prednisone \\> 10 mg\u002Fday for \\> 2 weeks within 3 months of screening (initiation of prednisone during the study is permitted if considered clinically indicated in the opinion of the treating physician)\n* Use of azathioprine, cyclophosphamide, rituximab, and\u002For tocilizumab within 3 months of screening (initiation of azathioprine, cyclophosphamide, rituximab, and\u002For tocilizumab during the study is permitted if considered clinically indicated in the opinion of the treating physician)\n* Use of pirfenidone and\u002For nintedanib within 6 weeks of screening (initiation of nintedanib and\u002For pirfenidone during the study is permitted if considered clinically indicated in the opinion of the treating physician)\n* Significant emphysema (\\> 10% volume on HRCT or FEV1\u002FFVC \\\u003C lower limit of normal)\n* Expected survival \\\u003C 6 months as determined by the treating physician",{"count":188,"type":20},120,[190],"PHASE4","This is a trial designed to evaluate the combination of nerandomilast with mycophenolate across a wide variety of pulmonary fibrosis subtypes, with the aim of providing clinicians with assurance that this is an appropriate therapeutic combination.",[26,127],[141,140,194,195,196],"nerandomilast","Mycophenolate mofetil","mycophenolate sodium","2026-05-05",{"date":199,"type":41},"2026-05-11",{"date":201,"type":20},"2026-06",{"date":203,"type":20},"2027-07",{"name":205,"class":79},"University of British Columbia",{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":217,"conditions":218,"keywords":227,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":230,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":80},"100565589","p4o2-ild-extension-100565589","NCT06644144","P4O2 ILD Extension","Early Identification of Progressive Pulmonary Fibrosis, Precision Medicine for More Oxygen - ILD Extension.","P4O2-ILD","Inclusion Criteria:\n\n* Diagnosis of (1) idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis (FPF), (2) other fibrotic ILDs (fILD), including fibrotic hypersensitivity pneumonitis (fHP), idiopathic non-specific interstitial pneumonia (iNSIP), connective tissue disease (CTD)-ILD, and unclassifiable ILD (uILD); or (3) interstitial lung abnormalities (ILA).\n* Meeting all the following criteria during the screening period:\n\n  1. FVC ≥45% predicted.\n  2. FEV1\u002FFVC ≥0.7.\n  3. DLco corrected for Hb ≥40% predicted.\n* Able to provide written informed consent as approved by the independent ethics committee.\n* Able to undergo a CT scan and perform PFT.\n* Age \\> 18 years and \\< 80 years.\n* Understanding of the Dutch or English language.\n\nExclusion Criteria:\n\n* Combined pulmonary fibrosis and emphysema (CPFE) diagnosis\n* Chronic obstructive lung disease (COPD) with an FEV1\u002FFVC \\<70%.\n* Uncontrolled severe asthma.\n* Active malignancy, except for squamous cell carcinoma of the skin, low-risk breast cancer, and low-risk prostate cancer.\n* Pregnancy or lactating.","80 Years",{"count":216,"type":20},450,"The goal of this observational study is to identify early biomarkers that can predict the development of progressive pulmonary fibrosis (PPF) in participants with interstitial lung diseases (ILDs). The participant population includes adults diagnosed with idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis (FPF), other fibrotic ILDs, and interstitial lung abnormalities (ILA).\n\nThe main questions it aims to answer are:\n\n* What biomarkers and risk factors are linked to fibrosis progression or can predict rapid worsening and sudden flare-ups in IPF and FPF patients?\n* What biomarkers and risk factors can predict the development of a PPF phenotype in different types of ILD?\n* What biomarkers and risk factors can help identify ILA patients who may develop significant ILD?\n* What biomarkers and risk factors can predict how well ILD patients will respond to treatment?\n\nResearchers will compare the outcomes between participants diagnosed with IPF\u002FFPF, other fibrotic ILDs, and ILA to see if early detection biomarkers differ among these groups.\n\nParticipants will:\n\n* Undergo blood sampling.\n* Perform lung function tests.\n* Have CT scans.\n* Perform breath analysis\n* Participate in exposome and microbiome analyses.\n* Complete questionnaires.\n* A subgroup of participants will be offered bronchoscopy.",[219,26,220,32,221,222,223,224,225,226],"Interstitial Lung Disease","Interstitial Lung Fibrosis","Pulmonary Fibrosis, Idiopathic","Pulmonary Fibrosis Idiopathic Familial","Chronic Hypersensitivity Pneumonitis","Unclassifiable ILD","Idiopathic NSIP","CTD-ILD",[219,228,229],"Interstitial Lung Abnormalities","Progressive Pulmonary Fibrosis",{"date":199,"type":41},{"date":232,"type":41},"2024-11-01",{"date":234,"type":20},"2031-10-01",{"name":236,"class":79},"Amsterdam UMC, location VUmc",{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":214,"enrollmentInfo":244,"targetDuration":4,"studyType":21,"phases":246,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":80},"100636953","phase-2-advanced-imaging-to-assess-the-effect-of-immunosuppression-on-progressive-fibrosis-100636953","NCT07572383","Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis","Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Lung Fibrosis in Participants With Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease","Inclusion Criteria:\n\n1. Age 18-80 with a diagnosis of chronic hypersensitivity pneumonitis, connective tissue-associated ILD (due to rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease), or undifferentiated ILD.\n2. Starting immunosuppression treatment with mycophenolate mofetil, mycophenolate sodium, and \u002F or prednisone for clinically indicated non-IPF ILD treatment.\n3. Pulmonary fibrosis, defined as honeycombing, traction bronchiectasis, or reticular opacities on high-resolution computed tomography (HRCT) performed within 1 year to or at Visit 1.\n4. Forced vital capacity (FVC) of \\>\u002F= 45% and diffusing capacity of the lungs for carbon monoxide (DLCO) \\>\u002F= 25% predicted on PFTs performed at Visit 1.\n\nExclusion criteria:\n\n1. Current or prior exposure to FDA approved anti-fibrotic therapy.\n2. Extent of emphysema greater than extent of fibrosis.\n3. Pregnancy or plans to become pregnant at baseline or during follow-up.\n4. Contraindications to MRI.\n5. Contraindications to receiving gadolinium-based contrast agents.\n6. Research-related radiation exposure exceeds 50 millisievert (mSv) in the prior year.\n7. Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin (only for individuals with a history of chronic kidney disease).\n8. Clinically significant pulmonary hypertension (PH) defined by use of pulmonary vasodilatory therapy.\n9. Respiratory infection within the prior 6 weeks.\n10. Smoking of any kind within the prior 6 months.",{"count":245,"type":20},15,[247],"PHASE2","The purpose of this study is to investigate how immunosuppression treatment affects measurements of active collagen deposition using \\[68Ga\\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in individuals with non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD).",[219,26],"2026-05-02",{"date":252,"type":41},"2026-05-07",{"date":254,"type":20},"2026-04",{"date":256,"type":20},"2028-12-31",{"name":258,"class":79},"Peter Caravan",{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":88,"sex":17,"minAge":58,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":21,"phases":268,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":80},"100610602","phase-1-study-on-the-drug-interactions-of-hrs-9813-pirfenidone-and-nintedanib-in-healthy-subjects-100610602","NCT07229716","Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form before the start of the related activities of this trial, and be able to understand the procedures and methods of this trial. Also, be willing to strictly follow the clinical trial protocol to complete this trial.\n2. Aged 18-45 years.\n3. Male weight ≥ 50 kg, female weight ≥ 45 kg, and body mass index (BMI): 19 - 28 kg\u002Fm2 (including both endpoints).\n4. Sign the informed consent form and, within 28 days after the last administration of the trial drug, have no intention of having children and agree to adopt non-drug methods of effective contraception, and have no plans for sperm donation or egg donation.\n\nExclusion Criteria:\n\n1. Those who are allergic to the study drugs (HRS-9813 capsules, nintedanib or pirfenidone), or any components of the study drugs, or have an allergic constitution (such as individuals with asthma, allergic rhinitis, or eczema).\n2. Those subjects who, in the judgment of the researchers, have any conditions or diseases that may affect the absorption, metabolism, and\u002For excretion of the study drug.\n3. Those who participated in any clinical trial of other drugs or medical devices within the previous 3 months before the screening period or baseline period, or those whose exposure to the drug is still within 5 half-lives during the study period (whichever is longer).\n4. During the screening period or baseline period, the sitting systolic blood pressure was less than 90 mmHg or the sitting diastolic blood pressure was less than 60 mmHg.\n5. During the screening period, any one of the following being positive: hepatitis B surface antigen (HBsAg), human immunodeficiency virus antibody, Treponema pallidum antibody or hepatitis C virus antibody.\n6. Pregnant or lactating women, or those whose blood pregnancy test results in the screening or baseline phase are positive.\n7. Those who have a history of blood donation within 8 weeks before the screening period or the baseline period, or have suffered from severe blood loss (blood loss ≥ 400 mL), or have received blood transfusion within 4 weeks before the screening period or the baseline period; or those who plan to donate blood during the trial.\n8. Those who were vaccinated within the two weeks prior to the screening period or the baseline period, or those who plan to receive the vaccine during the trial process.\n9. Those who have special dietary requirements and cannot follow the uniform diet.\n10. Those who have difficulty swallowing, have problems with venous blood collection, or whose physical condition does not allow for intensive blood sampling.\n11. Those who have had severe infections, severe trauma or undergone heavy manual surgery within 3 months before the screening period or baseline period; Or those who plan to undergo surgery during the trial period.\n12. During the screening period or baseline period, for those with abnormal 12-lead electrocardiogram results and clinical significance, the QTcB of men was \\> 450ms and that of women was \\> 460 ms.\n13. Those who have a history of smoking (smoking more than 5 cigarettes per day on average) within 3 months before the screening period or baseline period, or those who have a smoking history within 4 weeks before the screening period or baseline period, or those who cannot stop using any tobacco products during the trial period.\n14. Those who have a history of drug use or drug abuse\u002Fdependence before the screening period or baseline period; Or those with positive urine test results during the baseline period.\n15. Those who consumed excessive amounts of tea, coffee or caffeinated beverages (an average of more than 8 cups per day, 250 mL per cup) within 6 months prior to the screening period or baseline period.","45 Years",{"count":267,"type":20},20,[269],"PHASE1","This study aims to evaluate the interaction of oral HRS-9813 capsules with pirfenidone and nintedanib on the pharmacokinetics of healthy subjects.",[26],"2026-04-23",{"date":274,"type":41},"2026-04-27",{"date":276,"type":41},"2026-04-04",{"date":278,"type":20},"2026-05",{"name":280,"class":48},"Guangdong Hengrui Pharmaceutical Co., Ltd",{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":214,"enrollmentInfo":287,"targetDuration":4,"studyType":21,"phases":289,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":298,"locationsCount":80},"100556973","phase-2-advanced-imaging-for-pulmonary-fibrosis-100556973","NCT06532071","Advanced Imaging for Pulmonary Fibrosis","Inclusion Criteria:\n\n1. Age 18-80 with a diagnosis of chronic hypersensitivity pneumonitis, connective tissue-associated ILD (due to rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease), or undifferentiated ILD.\n2. On stable dose immunosuppression treatment (with prednisone, mycophenolate mofetil, mycophenolate sodium, and\u002For rituximab) for at least 3 months.\n3. Pulmonary fibrosis, defined as honeycombing, traction bronchiectasis, or reticular opacities on HRCT performed within 1 year to or at Visit 1.\n4. FVC of \\>\u002F= 45% and DLCO \\>\u002F= 25% predicted on PFTs performed at Visit 1.\n\nExclusion Criteria:\n\n1. Current or prior exposure to FDA approved anti-fibrotic therapy.\n2. Extent of emphysema greater than extent of fibrosis.\n3. Pregnancy or plans to become pregnant at baseline or during follow-up.\n4. Contraindications to MRI.\n5. Contraindications to receiving gadolinium-based contrast agents.\n6. Research-related radiation exposure exceeds 50 mSv in the prior year.\n7. Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin (only for individuals with a history of chronic kidney disease).\n8. Clinically significant PH defined by use of pulmonary vasodilatory therapy.\n9. Respiratory infection within the prior 6 weeks.\n10. Smoking of any kind within the prior 6 months.",{"count":288,"type":20},60,[247],"The purpose of this study is to determine if measurements of active collagen deposition using \\[68Ga\\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can predict an individual patient's pace of disease progression in non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD) and identify which individuals will develop progressive pulmonary fibrosis.",[26],"2026-04-17",{"date":294,"type":41},"2026-04-22",{"date":296,"type":41},"2025-01-21",{"date":256,"type":20},{"name":258,"class":79},{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":88,"sex":17,"minAge":58,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":21,"phases":308,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":80},"100628629","phase-1-application-of-68gaga-ni-fapi-04-petct-imaging-in-fibroblast-activation-protein-related-diseases-100628629","NCT07464132","Application of [68Ga]Ga-NI-FAPI-04 PET\u002FCT Imaging in Fibroblast Activation Protein Related Diseases","Inclusion Criteria:\n\n* 1: 18-85 years old\n\n  2: Tumor patients can undergo surgery or biopsy to obtain pathological diagnosis\n\n  3: Ability to understand and sign informed consent forms\n\n  4: Expected survival period exceeding 6 months and able to receive follow-up\n\n  5: Healthy volunteers without chronic medical history of hypertension, diabetes, coronary heart disease, kidney disease, tumor, etc\n\nExclusion Criteria:\n\n* 1: Pregnant or lactating women\n\n  2: Patients allergic to research drug ingredients\n\n  3: Patients with severe liver and kidney dysfunction (blood creatinine levels exceeding 159 μ mol\u002FL)\n\n  4: Patients who participate in other clinical trials and interfere with the results of this study\n\n  5: Patients with severe illness who cannot cooperate with the examination","85 Years",{"count":307,"type":20},30,[269,247],"The purpose of this study is to conduct clinical research on \\[68Ga\\] Ga-NI-FAPI-04 PET\u002FCT imaging and further investigate its diagnostic value in fibroblast activation related diseases.",[311,312,26,313,314,315],"Tumor","Cardiovascular Diseases","Rheumatic Immune Diseases Involving Large Blood Vessels","Hypertrophic Cardiomyopathy (HCM)","Other Hypoxic and Fibroblast Activated Diseases","2026-03-09",{"date":318,"type":41},"2026-03-11",{"date":320,"type":41},"2025-12-17",{"date":322,"type":20},"2027-06-17",{"name":324,"class":79},"Peking Union Medical College Hospital",{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":333,"conditions":334,"keywords":335,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":80},"100628251","clinical-application-of-68ga-1a12-pet-in-fibrosis-related-diseases-100628251","NCT07459205","Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases","Inclusion Criteria:\n\n* No gender restriction, age ≥18 years (inclusive);\n* patients suspected or confirmed to have fibrosis-related disease;\n* patients eligible for 68Ga-1A12 PET scan\n* Patients who can provide informed consent (signed by the participant, parent or legal representative) and consent forms in accordance with the guidelines of the clinical research ethics committee.\n\nExclusion Criteria:\n\n* patients in critical condition requiring emergency care;\n* Individuals with druand\u002For alcohol abuse, or those with allergic predisposition;\n* women of childbearing potential, pregnant and lactating women;\n* bacterial, viral or fungal infections that require systemic treatment;\n* The study excluded participants deemed unsuitable by the investigators.",{"count":332,"type":20},50,"Organ fibrosis is a common end-stage pathological change in various chronic diseases, characterized by excessive deposition of extracellular matrix (ECM) and disruption of tissue architecture, which can involve multiple organs such as the heart, liver, lungs, kidneys, and intestines. Although the pathogenic triggers vary, the core molecular mechanisms are highly conserved, involving sustained activation of signaling pathways such as transforming growth factor-β (TGF-β), transdifferentiation of fibroblasts into myofibroblasts, and processes like epithelial-mesenchymal transition (EMT) . Currently, histopathological biopsy remains the gold standard for the diagnosis and staging of fibrosis, but its inherent invasiveness, sampling errors, and procedural risks limit its repeated application and dynamic monitoring .\n\nIn clinical practice, functional imaging modalities such as high-resolution computed tomography (CT) and ultrasonic elastography have been employed to assess fibrosis in specific organs (e.g., lungs, liver). However, these methods predominantly rely on secondary morphological or physical property alterations, exhibiting limited capacity for identifying early-stage, active molecular-level pathological processes. Additionally, they are challenging to perform for systemic, multi-target quantitative evaluation.",[26],[336,337,26],"PET","68Ga-1A12","2026-03-08",{"date":318,"type":41},{"date":341,"type":20},"2026-03-01",{"date":343,"type":20},"2027-12-31",{"name":345,"class":79},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University",{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":88,"sex":17,"minAge":58,"maxAge":214,"enrollmentInfo":353,"targetDuration":4,"studyType":21,"phases":355,"briefSummary":356,"conditions":357,"keywords":359,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":80},"100326859","phase-1-preliminary-evaluation-of-68gacbp8-in-healthy-individuals-lung-cancer-and-idiopathic-pulmonary-fibrosis-patients-100326859","NCT03535545","Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients","Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer Patients Undergoing Radiation Therapy Prior to the Resection of Locally Advanced Tumors, and Idiopathic Pulmonary Fibrosis Patients","Inclusion Criteria: Total enrollment for all groups will not exceed 100 subjects.\n\n* Group 1: Healthy subjects\n* Age greater than 18 years\n* Be deemed healthy at screening visit as determined by the physician investigator or nurse practitioner, based on the following assessments at Screening: physical examination, medical history, and vital signs\n* Have the ability to give written informed consent;\n* No known history of pulmonary disease (excluding pulmonary nodules);\n* No prior history of tobacco use.\n\nGroup 2: Lung cancer subjects\n\n* Eligible patients will be those harboring locally advanced clinical stage IIIA NSCLC who are deemed candidates for multi-modality therapy, i.e. concurrent chemotherapy and radiation followed by pulmonary resection.\n* Age greater than 18 years\n* Have the ability to give written informed consent.\n* No tobacco use within the prior 6 months.\n\nGroup 3: Subjects with pulmonary fibrosis\n\n* IPF (with a UIP or probable UIP pattern); or other forms of interstitial lung disease (ILD), including CTD-ILD, with a fibrotic component as noted by the presence of reticular markings and \u002F or traction bronchiectasis and \u002F or honeycombing on CT;\n* Age: 40-80 years old;\n* Have the ability to give written informed consent;\n* No tobacco use within the prior 6 months\n\nGroup 4: Subjects with chronic lung allograft dysfunction (CLAD)\n\n* Status post lung transplantation\n* Clinical diagnosis of chronic lung allograft dysfunction\n* Age: 40-80 years old;\n* Have the ability to give written informed consent;\n* No tobacco use within the prior 6 months\n\nGroup 5: Subjects with immune-checkpoint-inhibitor (ICI) pneumonitis\n\n* CT findings with ground glass opacities \u002F consolidation or fibrotic changes with new onset during or within 3 months of receipt of ICI therapy\n* Age greater than 18 years\n* Have the ability to give written informed consent\n* No tobacco use within the prior 6 months\n\nExclusion Criteria:\n\n* Electrical implants such as cardiac pacemaker or perfusion pump;\n* Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, or steel implants ferromagnetic objects such as jewelry or metal clips in clothing;\n* eGFR of less than 30 mL\u002Fmin\u002F1.73 m2 within the past 90 days for group 4 subjects; history of chronic kidney disease for subjects in groups 1-3 and 5;\n* Pregnant or breastfeeding (a negative quantitative serum hCG pregnancy test is required for females having child-bearing potential before the subject can participate);\n* Claustrophobic reactions;\n* Research-related radiation exposure exceeds current Radiology Department guidelines (i.e. 50 mSv in the prior 12 months);\n* Unable to lie comfortably on a bed inside the MR-PET;\n* BMI \\> 33 (limit of the MRI table);\n* Determined by the investigator(s) to be clinically unsuitable for the study (e.g. based on screening visit and\u002For during study procedures);\n* Known history of pulmonary disease (except for pulmonary fibrosis in the study group, ICI pneumonitis in the study group, or CLAD in the study group), recent pneumonia or respiratory tract infections within 6 weeks of enrollment, prior radiation therapy to the thorax (except for the lung cancer patients in aim 2);\n* Pneumonia or other acute respiratory illness within 6 weeks of study entry (except for pulmonary fibrosis), pneumonia defined with elevated WBC, fever, infiltrate on CXR and need for antibiotics",{"count":354,"type":20},100,[269],"The goal of this study is to investigate the safety of \\[68Ga\\]CBP8 and its efficacy to detect collagen deposition in pulmonary fibrosis.",[26,358],"Lung Cancer",[360,361],"PET Imaging","Molecular Imaging","2026-02-25",{"date":364,"type":41},"2026-02-27",{"date":366,"type":41},"2018-08-01",{"date":368,"type":20},"2027-06-30",{"name":370,"class":79},"Massachusetts General Hospital",{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":380,"conditions":381,"keywords":382,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":80},"100096372","explanted-lung-tissues-with-pulmonary-fibrosis-100096372","NCT00515567","Explanted Lung Tissues With Pulmonary Fibrosis","Utilization of Explanted Lungs for Isolation of Tissue Samples and Primary Cell Lines to Study Pulmonary Fibrosis","Inclusion Criteria:\n\n* all patients awaiting lung transplant\n\nExclusion Criteria:\n\n* all who will not give consent",{"count":379,"type":20},90,"The goal of this study is to use the tissues from the explanted lungs in order to better study the cause of pulmonary fibrosis at a cellular level.",[26],[383,141],"explanted lungs","2026-01-12",{"date":386,"type":41},"2026-01-13",{"date":388,"type":4},"2006-02",{"date":390,"type":20},"2026-12",{"name":392,"class":79},"University of Chicago",{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":21,"phases":403,"briefSummary":404,"conditions":405,"keywords":408,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":419},"100563386","routine-vs-on-demand-ecmo-for-lung-transplantation-100563386","NCT06615492","Routine vs On-demand ECMO for Lung Transplantation","RoutinE Versus On-demand Intraoperative Extracorporeal Membrane Oxygenation (ECMO) During LUng TransplantatION (REVOLUTION)","REVOLUTION","Inclusion Criteria:\n\n* Patients undergoing lung transplant surgery\n\nExclusion Criteria:\n\n* Inability to provide consent for the study\n* Retransplantation\n* Multi-organ transplantation\n* Contra-indication to standard heparin anticoagulation (e.g., heparin-induced thrombocytopenia)\n* Lung transplant recipients where intraoperative cardiopulmonary support is mandatory:\n* Severe pulmonary hypertension (PH):\n\n  1. Systolic pulmonary artery pressure (PAP) ≥ 80 mm Hg on the most recent echocardiography, right heart catheterization, or pulmonary artery catheter measurement\n  2. Mean PAP ≥ 55 mm Hg on the most recent echocardiography, right heart catheterization, or pulmonary artery catheter measurement\n  3. The ratio of mean pulmonary to systemic artery pressure of \\> 0.66\n* Moderate to severe right ventricular (RV) hypokinesis or dysfunction\n* Left ventricular dysfunction: Defined as ejection fraction (LVEF) less than 45% on echocardiography, ventriculography, computed tomography (CT), or magnetic resonance imaging (MRI)\n* Patients requiring concomitant cardiac surgery: For example, significant coronary artery disease (CAD) requiring surgical grafting",{"count":402,"type":20},218,[163],"Lung transplantation is a complex procedure performed in patients with terminal lung disease. The transplant procedure stresses the patient's heart and lungs, which are already taxed by the underlying disease process. The heart-lung machine is occasionally used to support the patient and ensure adequate oxygen supply to other organs during the operation. It can be used routinely in all patients or selectively in patients who exhibit reduced oxygen supply to the remaining organs. This process, known as cardiopulmonary bypass (CPB), pumps blood out of the body to a heart-lung machine that removes carbon dioxide and returns oxygen-filled blood to the body.\n\nAlthough using the CPB increases the risk of bleeding, infection, and coagulation complications, it should still be considered in high-risk patients to compensate for more severe complications such as kidney failure and stroke caused by a lack of cardiopulmonary support. Extracorporeal membrane oxygenation (ECMO) is a recently developed CPB variation associated with fewer bleeding complications. It has recently replaced the traditional heart-lung machine as the preferred method of cardiopulmonary support during lung transplantation. Since ECMO is associated with fewer complications than standard CPB, many centers have increased their use of ECMO during lung transplantation. Some have even employed it routinely. However, there remains significant debate on how often it should be used.\n\nTherefore, the study's main objective is to compare the two approaches in lung transplantation, i.e., routine use versus selective use, and to determine if one approach is preferable to the other.",[406,127,26,407],"Respiratory Failure","COPD (Chronic Obstructive Pulmonary Disease)",[409,410],"ECMO","Lung Transplantation",{"date":412,"type":41},"2025-12-23",{"date":414,"type":41},"2024-11-05",{"date":416,"type":20},"2029-01-15",{"name":418,"class":79},"Centre hospitalier de l'Université de Montréal (CHUM)",4,{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":430,"conditions":431,"keywords":432,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":80},"100077096","genetic-polymorphisms-in-idiopathic-pulmonary-fibrosis-ipf-100077096","NCT00258570","Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)","Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis","GP","Inclusion Criteria:\n\n* 18 years of age or older\n* Diagnosis of pulmonary fibrosis confirmed by physical examination, pulmonary function testing, chest X-ray, and computed tomography (CT) scans.\n* Adult patients who are seeking treatment at the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease.\n\nExclusion Criteria:\n\n* Under 18 years of age\n* Non-fibrotic ILD",{"count":429,"type":20},2000,"The purposes of this study are:\n\n* to determine if there are specific genetic traits that might explain why patients have developed pulmonary fibrosis;\n* to determine if specific genetic traits account for differing patterns of inflammation and scar tissue that has formed in the patient's lungs.",[26],[433],"\"Lung[A04.400]\"","2025-11-11",{"date":436,"type":41},"2025-11-12",{"date":438,"type":4},"2003-01",{"date":440,"type":20},"2035-07",{"name":442,"class":79},"University of Pittsburgh",{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":451,"targetDuration":453,"studyType":61,"phases":4,"briefSummary":454,"conditions":455,"keywords":459,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":80},"100469443","interstitial-lung-disease-research-unit-biobank-100469443","NCT05392881","Interstitial Lung Disease Research Unit Biobank","University of Kansas Medical Center Interstitial Lung Disease Research Unit (ILDRU) Biobank","ILDRU","Inclusion Criteria:\n\n1. The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP)\n2. The participant is being followed for the presence of autoimmune disease, ILD or other rare lung diseases at TUKHS.\n3. The participant is ≥ 18 years of age.\n4. The participant has signed an approved consent for this study (living patients only)",{"count":452,"type":20},1000,"10 Years","Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.",[219,456,457,26,458],"Sarcoidosis","Idiopathic Pulmonary Fibrosis","Hypersensitivity Pneumonitis",[219,456,457,26,458],"2025-09-16",{"date":462,"type":41},"2025-09-22",{"date":464,"type":41},"2021-08-09",{"date":466,"type":20},"2032-03-01",{"name":468,"class":79},"University of Kansas Medical Center",{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":21,"phases":478,"briefSummary":480,"conditions":481,"keywords":486,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":494,"locationsCount":80},"100467364","early-phase-1-fapi-pet-for-lung-fibrosis-100467364","NCT05365802","FAPI PET for Lung Fibrosis","PET Study of 68Ga-FAPi-46 in Patients With Interstitial Lung Disease: an Exploratory Biodistribution Study With Histopathology Validation.","FAPI ILD","Inclusion criteria\n\n* Patients with ILD confirmed by CT at time of staging\n* Patients who have initiated or will initiate a new ILD medication with 3 months of enrollment OR Patients who are scheduled to undergo tissue biopsy or surgery of the lung\n* Patients are ≥ 18 years old at the time of the radiotracer administration\n* Patient can provide written informed consent\n\nExclusion criteria\n\n* Patient is pregnant or nursing\n* Patients with active infectious lung disease\n* Patients not expected to comply with the protocol requirements, not able to understand or follow trial procedures",{"count":307,"type":20},[479],"EARLY_PHASE1","This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD).\n\nThe purpose of this research study is to determine where and to which degree the FAPI tracer (68Ga-FAPI-46) accumulates in normal and fibrotic lung tissues of patients with interstitial lung disease.\n\nThe study will include patients with interstitial lung disease who have or will initiate a new ILD medication OR will undergo tissue biopsy or surgery of the lung.\n\nThe study will include 30 patients, the upper limit for PET imaging studies conducted under the Radioactive Drug Research Committee (RDRC) purview.\n\nParticipants will be injected with up to 7 mCi of 68-GaFAPi and will undergo one PET\u002FCT scan and one High Resolution CT of the lungs.\n\nThe study is sponsored by Ahmanson Translational Theranostic Division at UCLA.",[219,482,483,458,484,485,26],"Idiopathic Interstitial Pneumonias","Drug-Induced Pneumonitis","Radiation Pneumonitis","Pneumoconiosis",[140,141,487],"68Ga-FAPi-46","2025-06-30",{"date":490,"type":41},"2025-07-03",{"date":492,"type":41},"2021-11-16",{"date":390,"type":20},{"name":78,"class":79},{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":88,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":501,"targetDuration":503,"studyType":61,"phases":4,"briefSummary":504,"conditions":505,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":80},"100468652","pulmonary-fibrosis-foundation-community-registry-100468652","NCT05382572","Pulmonary Fibrosis Foundation Community Registry","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated informed consent form online\n2. Male or female, aged 18 or older\n3. Affected by PF as a member of at least one of the following cohorts:\n\n   1. An individual diagnosed with PF or ILD, including those who are post lung transplant, or\n   2. An individual who has cared (currently or in the past) for an individual with PF or ILD, and \u002F or\n   3. A family member (defined as parent, full or half-sibling, or child) of an individual with PF or ILD.\n4. Has internet access and a valid email address.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Primary residence or place of care is outside of the US.\n2. Inability or unwillingness of a participant to provide informed consent or comply with study protocol.\n3. Any condition or circumstance not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.\n4. Patients who were diagnosed with any of the below lung diseases. Similarly caregivers and family members associated with these diseases would be excluded.\n\n   * Sarcoid\n   * Lymphangioleiomyomatosis (LAM)\n   * Pulmonary alveolar proteinosis (PAP)\n   * Cystic fibrosis (CF)\n   * Amyloidosis",{"count":502,"type":20},10000,"5 Years","Pulmonary fibrosis (PF) results from a diverse group of health conditions and affects the lives of patients (including those who are post lung transplant), caregivers and family members. The Pulmonary Fibrosis Foundation Community Registry will offer an online portal where participants can self-enroll and directly contribute information about their experience with PF to be compiled into a longitudinal data set for use by researchers.",[26,219,506,457],"Lung Fibrosis","2025-04-08",{"date":509,"type":41},"2025-04-11",{"date":511,"type":41},"2022-07-11",{"date":513,"type":20},"2027-07-01",{"name":515,"class":79},"Pulmonary Fibrosis Foundation",{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":522,"targetDuration":4,"studyType":21,"phases":524,"briefSummary":525,"conditions":526,"keywords":528,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":419},"100525476","a-randomised-clinical-trial-of-a-digital-self-management-package-for-people-with-interstitial-lung-disease-100525476","NCT06122233","A Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease","Inclusion Criteria:\n\n* Diagnosis of fibrotic ILD\n* In possession of a smartphone\u002Ftablet and an email address\n* Able to understand written and spoken English\n* Adequate digital literacy to complete requirements of trial\n* On stable ILD treatment for 30 days prior to enrolment\n\nExclusion Criteria:\n\n* Not in possession of a smartphone\u002Ftablet\n* Insufficient digital literacy to complete requirements of trial\n* Unable to communicate in written\u002Fspoken English\n* Not on stable ILD treatment for 30 days prior to enrolment\n* Acute exacerbation within 30 days prior to enrolment\n* Participating in pulmonary rehab at enrolment or during 12-week intervention period\n* Unable to provide informed consent",{"count":523,"type":20},400,[163],"The goal of this clinical trial is to compare REBUILD-SM (a purpose-built smartphone app and self-management package) with standard care in people with interstitial lung disease (ILD). The main question it aims to answer is:\n\n• Does REBUILD-SM improve health-related quality of life, symptoms, anxiety, self-efficacy and physical activity for people with ILD?\n\nParticipants in the intervention group will work through the self-management package with support from a healthcare professional via phone or Zoom. They will also enter deidentified health data into the RE-BUILD smartphone app to track their progress over time. Participants in the control group will use a reduced functionality version of the smartphone app only.\n\nResearchers will compare both groups to see if there is any difference in health-related quality of life, symptoms, anxiety, self-efficacy and level of physical activity.",[527,26],"Lung Diseases, Interstitial",[529,530],"Self-Management","Chronic diseases","2025-04-01",{"date":533,"type":41},"2025-04-04",{"date":535,"type":41},"2024-06-03",{"date":537,"type":20},"2027-08",{"name":539,"class":79},"University of Sydney",{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":305,"enrollmentInfo":547,"targetDuration":4,"studyType":21,"phases":549,"briefSummary":550,"conditions":551,"keywords":554,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":114},"100421383","a-non-pharmacological-cough-control-therapy-100421383","NCT04767074","A Non-pharmacological Cough Control Therapy","A Non-pharmacological Cough Control Therapy as an Adjuvant of Pulmonary Rehabilitation in People With Interstitial Lung Diseases and Chronic Cough - A Feasibility Study","Inclusion Criteria:\n\n* Individuals will be included if having confirmed diagnosis of any ILD by a physician (as per Canadian Thoracic Society's guideline for evaluating patients with fibrotic interstitial lung disease) and a chronic cough lasting more than 8 weeks in duration\n\nExclusion Criteria:\n\n* self-reports of moderate or large sputum production\n* effective or suspected exacerbation of the respiratory condition in the past month\n* upper respiratory tract infection in the past month\n* use of angiotensin-converting enzyme inhibitor medication\n* changes in the prescribed medication in the previous month\n* evidence of traction bronchiectasis in the HRCT\n* evidence of other medical conditions that prevent performance of an exercise training program\n* unable to read or speak in English \u002F unable to provide informed consent.",{"count":548,"type":20},24,[163],"Coughing affects almost all individuals with ILD leading to physical, psychological and social distress and prevents individuals from performing their activities of daily living, working or socialising in public places. Unfortunately, there are no licensed medications available to treat chronic cough and the few drugs that have been tried resulted in little efficacy and significant side effects. Drug-free cough control interventions have shown promise in reducing the severity and impact of coughing on patients' lives but have not been tested in individuals with ILD. This study aims to explore the feasibility and effectiveness of a non-pharmacological cough control therapy, as an adjuvant of pulmonary rehabilitation, in patients with ILD and chronic cough (\\>8 weeks in duration).",[552,135,553,26],"Cough","Pulmonary Disease",[552,135,555,556,557],"Pulmonary rehabilitation","chronic cough","non-pharmacological cough therapy","2025-03-28",{"date":560,"type":41},"2025-04-03",{"date":562,"type":41},"2020-09-01",{"date":564,"type":20},"2025-12",{"name":566,"class":79},"West Park Healthcare Centre",{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":88,"sex":17,"minAge":58,"maxAge":574,"enrollmentInfo":575,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":576,"conditions":577,"keywords":591,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":602,"locationsCount":80},"100556693","identification-of-multiple-pulmonary-diseases-using-volatile-organic-compounds-biomarkers-in-human-exhaled-breath-100556693","NCT06528418","Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath","Exploration and Study on the Identification of Various Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath","Inclusion Criteria:\n\n* Males or females, age must be 18 years old or above.\n* Patients must meet the CT imaging diagnostic criteria for different lung diseases, and patients must be able to provide electronic versions of CT image data.\n* Patients must have a clear clinical diagnosis.\n* All participants must sign a written informed consent form.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Individuals with a history of cancer other than lung disease.\n* Individuals who have undergone organ transplants or non-autologous (allogeneic) bone marrow or stem cell transplants.\n* Individuals with other severe organic diseases or mental illnesses.\n* Individuals with metabolic diseases such as diabetes, hyperlipidemia, etc.\n* Any other condition that researchers deem unsuitable for participation in this clinical trial.","100 Years",{"count":502,"type":20},"The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) marker molecules. This model aims to accurately diagnose mutiple pulmonary diseases. The primary objectives it strives to accomplish are:\n\n1. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in diagnose several common pulmonary diseases.\n2. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in diagnose more pulmonary diseases.",[358,578,579,580,26,581,582,583,584,585,586,587,588,589,219,590],"Lung Infection","COPD","Bronchitis","Pulmonary Embolism","Pulmonary Arterial Hypertension","Pulmonary Tuberculosis","Pulmonary Abscess","Emphysema","Lung Injury","Cystic Fibrosis of the Lung","Bronchial Asthma","Bronchiectasis","Preserved Ratio Impaired Spirometry",[553,592,593,594,595],"Volatile Organic Compounds","Human Exhaled Breath","micro Gas Chromatography-photoionisation","detector (μGC-PID) system","2025-03-23",{"date":598,"type":41},"2025-03-26",{"date":600,"type":41},"2024-06-30",{"date":368,"type":20},{"name":603,"class":48},"ChromX Health",{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":4,"eligibilityCriteria":610,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":214,"enrollmentInfo":611,"targetDuration":4,"studyType":21,"phases":612,"briefSummary":613,"conditions":614,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":80},"100535427","application-of-transbronchial-cryobiopsy-in-the-diagnosis-of-progressive-pulmonary-fibrosis-100535427","NCT06251687","Application of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis","Application of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis：a Multicenter Prospective Study","Inclusion Criteria:\n\nPatients with PPF, ≥18 years of age, unclassified ILD, HRCT ≤3 months, forced vital capacity (FVC)≥50% predicted value, pulmonary carbon monoxide diffusion (DLCO)≥35% predicted value, echocardiography ≤12 months, estimated pulmonary systolic blood pressure ≤40 mmHg, Body mass index (BMI)≤35 kg\u002Fm2.\n\nExclusion Criteria:\n\nPatients with platelet counts below 50,000×109\u002FL or International Normalized ratio of prothrombin time (INR) above 1.5 are not eligible for TBLC",{"count":354,"type":20},[163],"The goal of this clinical study is to learn about the diagnostic effectiveness, safety, and influencing factors of transbronchial cryobiopsy（TBLC）in progressive pulmonary fibrosis. The main question it aims to answer are: • Determine the prognosis, health economics, and therapeutic strategy changes of patients with TBLC retrograde malleable pulmonary fibrosis. Participants will be randomly divided into two groups, and received TBLB or TBLC.",[26,615],"Transbronchial Cryobiopsy","2025-02-07",{"date":618,"type":41},"2025-02-10",{"date":620,"type":41},"2024-02-01",{"date":622,"type":20},"2026-12-31",{"name":624,"class":79},"China-Japan Friendship Hospital",{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":629,"acronym":4,"eligibilityCriteria":630,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":214,"enrollmentInfo":631,"targetDuration":4,"studyType":21,"phases":633,"briefSummary":634,"conditions":635,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":636,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":80},"100448617","phase-1-head-to-head-comparison-of-diagnosis-value-of-pulmonary-fibrosis-on-68ga-fapi-04-and-18f-fdg-pet-ct-100448617","NCT05121779","Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT","Inclusion Criteria:\n\n* suspected or confirmed pulmonary fibrosis patients;\n* signed written consent.\n\nExclusion Criteria:\n\n* pregnancy;\n* breastfeeding;\n* known allergy against FAPI\n* any medical condition that in the opinion of the investigator may significantly interfere with study compliance",{"count":632,"type":20},80,[269],"68Ga-fibroblast activating protein inhibitors(FAPI) has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation,such as inflammatory bowel disease. And it might be more sensitive than FDG in detecting a certain type of inflammations according to our preliminary research. Thus this prospective study is going to investigate whether 68Ga-FAPI PET\u002FCT may be superior for diagnosis, therapy response assessment and follow-up of Pulmonary fibrosis than 18F-FDG PET\u002FCT.",[26],"2024-11-21",{"date":638,"type":41},"2024-11-25",{"date":640,"type":41},"2021-11-18",{"date":642,"type":20},"2025-12-31",{"name":324,"class":79},{"id":645,"slug":646,"hasResults":12,"nctId":647,"briefTitle":648,"officialTitle":649,"acronym":650,"eligibilityCriteria":651,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":305,"enrollmentInfo":652,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":654,"conditions":655,"keywords":659,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":663,"lastUpdatePostDateStruct":664,"startDateStruct":666,"completionDateStruct":668,"leadSponsor":670,"locationsCount":80},"100570052","precision-diagnosis-and-care-for-families-with-pulmonary-fibrosis-in-ireland-100570052","NCT06702228","Precision Diagnosis and Care for Families With Pulmonary Fibrosis in Ireland","Precision Diagnosis and Care for Families With Pulmonary Fibrosis in Ireland [PRECISE-PF]","PRECISE-PF","Inclusion Criteria:\n\n* Able and willing to give written informed consent.\n* An MDT diagnosis of fibrotic ILD which fall into one of the following three catagories;\n\n  1. Have a multidisciplinary team (MDT) diagnosis of a fibrotic interstitial lung disease, reporting one or more relatives with a fibrotic form of ILD\n  2. Have a MDT diagnosis of IPF in accordance with consensus criteria, ATS, ERS, JRS, ALAT guidelines without a family history of pulmonary fibrosis.\n  3. Meet the American College of Rheumatology\u002FEuropean League Against Rheumatism criteria for rheumatoid arthritis, scleroderma, Sjogren's syndrome, idiopathic inflammatory myopathy and systemic lupus erythematosus.\n\nExclusion Criteria:\n\n* Currently participating in an interventional clinic trial.\n* Change in clinical phenotype from initial radiological diagnosis to screening.\n* Acute or chronic hypersensitivity pneumonitis with consensus criteria (appropriate exposure history, radiological features ± avian and fungal precipitins).\n* Asbestosis (appropriate occupational history and radiological evidence of asbestos exposure)\n* Life expectancy for any disease, including ILD \\\u003C12 months (investigator assessment)\n* Major extrapulmonary physiological restriction (e.g. chest wall abnormality, large pleural effusion)",{"count":653,"type":20},300,"This study aims to improve the understanding of how genes and the environment can influence and cause pulmonary fibrosis. By identifying the presence of genes and other factors that can put people at risk of developing pulmonary fibrosis, the influence these factors have on the progression of the disease can be studied.\n\nInterstitial lung disease (ILD) is the medical term given to a group of lung diseases affecting the same part of the lung, the interstitium, each with similar symptoms. In some of these diseases, inflammation leads to lung scarring, known as fibrosis. Idiopathic Pulmonary Fibrosis (IPF) is one of these diseases; it has a particular pattern on computed tomography (CT) scans. IPF is 'idiopathic' as it is not yet fully understood why it happens. It has a poor prognosis. The average survival time is three to five years after diagnosis. While new antifibrotic drugs offer hope of slowing disease progression, lung transplant is the only cure, and it comes with its significant risks.\n\nAlthough it is not fully understood what causes IPF, it is known that genetic factors significantly increase the risk of developing the disease. Up to a quarter (25%) of people with IPF with a family history appear to have a causative genetic variant. Familial-pulmonary-fibrosis (FPF), the term for people with at least one relative with IPF, may have worse disease when compared to those without a family history. However, this needs more research. Patients with specific genes, telomere-related gene variants, appear to have a greater risk of developing blood disorders from medications given to suppress the body's immune system after a lung transplant.\n\nProgressive pulmonary fibrosis is pulmonary fibrosis where there is irreversible worsening of the disease, worsening of lung function, respiratory symptoms and even early death. It is of growing importance regardless of the cause, whether it be idiopathic, familial or secondary to a connective tissue disease. ILD is increasingly recognised as a complication of connective tissue diseases. It is the leading cause of death in people with systemic sclerosis. The new antifibrotic drugs slow the progression of CTD-ILD. People with progressive pulmonary fibrosis who have a greater than 10% drop over one year in a measure of their lung function, called the forced vital capacity, benefit most from antifibrotic therapy. Early identification of people with progressive disease would allow the commencement of treatment quicker. At-home spirometry may be a way of identifying those who are worsening early.\n\nThis study hypothesises that by improving knowledge of factors that affect disease behaviour and progression and assessing tools for the early identification of progressive disease, such as at-home spirometry and CT scan pattern determination by deep-learning analysis, we can provide 'precision' diagnosis and treatment. It is hoped that this improved understanding will help reduce the clinical risk for people with pulmonary fibrosis and their families.\n\nThis study aims to recruit 300 patients: 100 with IPF, 100 with FPF, and 100 with CTD ILD. Each participant will be followed for one year.\n\nThis observational study aims to help answer a number of questions:\n\n1. What genetic variants cause people to develop ILD, and which increase a person's risk of developing ILD are present in the study population?\n2. How does pulmonary fibrosis behave in people who have a family history of IPF compared to those who do not and in people with CTD-ILD?\n3. Are different types of pulmonary fibrosis more progressive than others i.e. Is pulmonary fibrosis in those with a family history of pulmonary fibrosis more progressive than in those who do not have a family history?\n4. Is the disease in those with a genetic variant known to cause ILD worse than in those who don't have a gene?\n5. Can at-home spirometry help identify people at risk of progressive disease early?\n6. Can deep-learning analysis (AI) be used to find CT scan patterns to predict when pulmonary fibrosis will worsen?",[656,219,457,657,26,658],"Connective Tissue Diseases","Familial Idiopathic Pulmonary Fibrosis","Pulmonary Fibrosis Interstitial",[660,661,662,26,482],"Genetic diseases","Diagnosis, Computer-assisted","Early Diagnosis","2024-11-20",{"date":665,"type":41},"2024-11-22",{"date":667,"type":41},"2021-09-28",{"date":669,"type":20},"2028-04-01",{"name":671,"class":79},"Royal College of Surgeons, Ireland"]